F
Farinaz Safavi
Researcher at Thomas Jefferson University
Publications - 32
Citations - 1765
Farinaz Safavi is an academic researcher from Thomas Jefferson University. The author has contributed to research in topics: Experimental autoimmune encephalomyelitis & Medicine. The author has an hindex of 11, co-authored 25 publications receiving 1329 citations. Previous affiliations of Farinaz Safavi include SUNY Downstate Medical Center & King's College London.
Papers
More filters
Journal ArticleDOI
The encephalitogenicity of T(H)17 cells is dependent on IL-1- and IL-23-induced production of the cytokine GM-CSF.
Mohamed El-Behi,Bogoljub Ciric,Hong Dai,Yaping Yan,Melissa Cullimore,Farinaz Safavi,Guang-Xian Zhang,Bonnie N. Dittel,Abdolmohamad Rostami +8 more
TL;DR: Cross-regulation of IL-23 and GM- CSF explains the similar pattern of resistance to autoimmunity when either of the two cytokines is absent and identifies TH17 cells as a crucial source of GM-CSF in autoimmune inflammation.
Journal ArticleDOI
B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran.
TL;DR: Whether the course of COVID-19 is more severe in patients with MS and if MS disease-modifying treatments (DMTs) affect the risk of contracting the disease is determined and B-cell depleting antibodies may increase the susceptibility to contracting CO VID-19.
Journal ArticleDOI
Expression of GM-CSF in T Cells Is Increased in Multiple Sclerosis and Suppressed by IFN-β Therapy
Javad Rasouli,Bogoljub Ciric,Jaime Imitola,Patricia Gonnella,Daniel Hwang,Kedar R Mahajan,Elisabeth R. Mari,Farinaz Safavi,Thomas Leist,Guang-Xian Zhang,Abdolmohamad Rostami +10 more
TL;DR: To characterize GM-CSF production by T cells of MS patients and to determine the effect of IFN-β therapy on its production, a potential mechanism ofIFN- β therapy, namely suppression of GM- CSF production is revealed.
Journal ArticleDOI
Role of serine proteases in inflammation: Bowman–Birk protease inhibitor (BBI) as a potential therapy for autoimmune diseases
TL;DR: The Bowman-Birk protease inhibitor (BBI), a soybean-derived serine protease inhibitors, is resistant to temperature and acidic conditions, which makes it a good candidate for oral administration, with no major side effects.
Journal ArticleDOI
Neurovascular injury with complement activation and inflammation in COVID-19
Myoung Hwa Lee,Daniel P. Perl,Joseph P. Steiner,Nick Pasternack,Wenxue Li,Dragan Maric,Farinaz Safavi,Iren Horkayne-Szakaly,Robert V. Jones,Michelle N Stram,Joel T. Moncur,Marco M. Hefti,Rebecca D. Folkerth,Avindra Nath +13 more
TL;DR: Antibody-mediated cytotoxicity directed against the endothelial cells is the most likely initiating event that leads to vascular leakage, platelet aggregation, neuroinflammation and neuronal injury in patients with coronavirus disease 2019.